

ACTA MEDICINAE Speciál 2015 Kompletní literatura

Kazuistiky v onkologii a hematoonkologii

- 2 **Effentora v léčbě průlomové bolesti**
MUDr. Marek Hakl Centrum pro léčbu bolesti, ARK, LF MU a FN u sv. Anny v Brně
- 2 **Řešení nutričních problémů pacientky s karcinomem žaludku**
MUDr. Milana Šachlová, CSc., Ph.D. Gastroenterologické oddělení, MOÚ v Brně
- 2 **Aprepitant u rizikové pacientky se středně emetogenní chemoterapií**
doc. MUDr. Miroslav Tomíška, CSc. | MUDr. Lada Klvačová | MUDr. Dagmar Brančíková
Interní hematologická a onkologická klinika LF MU a FN Brno
- 2 **Kombinovaný preparát Targin v léčbě bolesti u mnohočetného myelomu**
doc. MUDr. Luděk Pour, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno-Bohunice
- 3 **Regorafenib v léčbě pokročilého gastrointestinálního stromálního tumoru**
MUDr. Zdeněk Linke Onkologická klinika 2. LF UK a FN Motol, Praha
MUDr. Pavel Fencel, CSc. Oddělení nukleární medicíny a PET centrum, Nemocnice Na Homolce, Praha
- 3 **Využití bevacizumabu u nemocných s metastatickým karcinomem prsu**
doc. MUDr. Luboš Holubec, Ph.D., MBA Radioterapeutická a onkologická klinika, FN a LF v Plzni, UK v Praze, Plzeň,
Biomedicínské centrum, LF v Plzni, UK v Praze, Plzeň
MUDr. Taťána Fischerová | prof. MUDr. Jindřich Fínek, Ph.D., MHA
Radioterapeutická a onkologická klinika, FN a LF v Plzni, UK v Praze, Plzeň
- 3 **Dolforin – klinická zkušenost v léčbě chronické bolesti u onkologických a neonkologických pacientů**
MUDr. Jitka Fricová, Ph.D. KARIM, Centrum pro léčbu bolesti 1. LF UK a VFN Praha
- 4 **Aflibercept, první zkušenosti v léčbě metastatického karcinomu kolorekta**
MUDr. Dagmar Brančíková | MUDr. Otakar Bednařík, CSc.
Interní hematologická a onkologická klinika, LF a FN Brno
- 4 **Léčba chronické myeloidní leukemie dasatinibem s pozitivním vlivem na kompenzaci diabetu**
MUDr. Petra Bělohlávková IV. interní hematologická klinika, FN a LF UK Hradec Králové
- 4 **Mobilizace hematopoetických kmenových buněk plerixaforem**
doc. MUDr. Jan Novák, Ph.D. Interní hematologická klinika 3. LF UK a FNKV Praha
- 4 **Léčba staršího nemocného s relabující chronickou lymfocytární leukemií**
MUDr. Pavel Vodárek | doc. MUDr. Lukáš Smolej, Ph.D.
IV. interní hematologická klinika, FN a LF UK Hradec Králové
- 5 **Noxafil 100 mg enterosolventní tablety (posaconazolom) – lékový profil**
MUDr. Jiří Slíva, MD., Ph.D. Ústav farmakologie 2. a 3. LF UK Praha

Effentora v léčbě průlomové bolesti

MUDr. Marek Hakl Centrum pro léčbu bolesti, ARK, LF MU a FN u sv. Anny v Brně

- 1 **Kabelka, L. – Kozák, J. – Lejško, J. – Sláma, O.:** Doporučený postup pro léčbu průlomové bolesti. *Bolest*, 2011, 14, dopl. 1.
- 2 **Webster, L. R.:** Breakthrough pain in the management of chronic persistent pain syndromes. *Am J Manag Care*, 2008, 14, s. 116–122.
- 3 **Dickman, A.:** Integrated strategies for the successful management of breakthrough cancer pain. *Curr Opin Support Palliat Care*. 2011, 5, s. 8–14.
- 4 **Fortner, B. V. – Okon, T. A. – Portenoy, R. K.:** A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. *J Pain*, 2002, 3, s. 38–44.

Řešení nutričních problémů pacientky s karcinomem žaludku

MUDr. Milana Šachlová, CSc., Ph.D. Gastroenterologické oddělení, MOÚ v Brně

- 1 **Bozzetti, F.:** Nutritional support in oncologic patients: where we are and where we are going. *Clin Nutr*, 2011, 30, s. 714–717.
- 2 **Fearon, K. – Strasser, F. – Anker, S. D.:** Definition and classification of cancer cachexia: an international consensus. *Lancet Oncology*, 2011, 12, s. 489–495.
- 3 **ESPEN guidelines on adult enteral nutrition**, *Clin Nutr*, 2006, 25, s. 177–360.
- 4 **Bozzetti, F.:** Nutritional support of the oncology patient. *Critical Rev in Oncology/Hematology*, 2013, 87, s. 172–200.
- 5 **Ravasco, P. – Monteiro-Grillo, I. – Vidal, P. M. – Camilo, M. E.:** Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. *J Clin Oncol*, 2005, 23, s. 1431–1438.
- 6 **Zadák, Z.:** *Výživa v onkologii. Breviř 2012/2013*. Medical Tribune, s. 42–43.
- 7 **Ganze, A.:** New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition. *Experimental and therapeutic medicine*, 2011, 2, s. 675–684.
- 8 **Deutz, N. E. P. – Safar, A. – Schutzler, S., et al.:** Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medicinal food. *Clinical Nutrition*, 2011, 30, s. 759–768.
- 9 **Spies, C. D. – Breuer, J. P. – Gust, R., et al.:** Preoperative fasting, an update. *Anaesthesist*, 2003, 52, s. 1039–1045.
- 10 **Fearon, K. C. – Ljungqvist, O. – Von Meyenfeldt, M., et al.:** Enhanced recovery after surgery: a consensus review of clinical care for patients undergoing colonic resection. *Clin Nutr*, 2005, 24, s. 466–477.
- 11 **Tomáška, M.:** *Výživa nemocných*. In: Souček, M.: *Vnitřní lékařství*. Grada Publishing, 2. díl, s. 1533–1558.
- 12 **Keller, U. – Meier, R. – Bertoli, S.:** *Klinická výživa*. Scientia medica, 1993.
- 13 **Dewys, W. D. – Begg, C. – Lavin, P. T., et al.:** Prognostic effect of weight loss prior to chemotherapy in cancer patients. *Am J Med*, 1980, 69, s. 491–497.

Aprepitant u rizikové pacientky se středně emetogenní chemoterapií

doc. MUDr. Miroslav Tomáška, CSc. | MUDr. Lada Klvačová | MUDr. Dagmar Brančíková
Interní hematologická a onkologická klinika LF MU a FN Brno

- 1 **Hesketh, P. J. – Grunberg, S. M. – Gralla, R. J., et al.:** The oral neurokinin-1 antagonist aprepitant for the chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. *J Clin Oncol*, 2003, 21, s. 4112–4119.
- 2 **Polli-Bigeli, S. – Rodrigues-Pereira, J. – Carides, A. D., et al.:** Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. *Cancer*, 2003, 97, s. 3090–3098.
- 3 **Herrstedt, J. – Muss, H. B. – Warr, D. G. – Hesketh, P. J., et al.:** Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. *Cancer*, 2005, 104, s. 1548–1555.
- 4 **Majem, M. – Moreno, M. E. – Calvo, N., et al.:** Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. *Support Care Cancer*, 2011, 19, s. 1983–1990.
- 5 **Ihbe-Heffinger, A. – Ehlen, B. – Bernard, R., et al.:** The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilisation and costs in German cancer centers. *Ann Oncol*, 2004, 15, s. 526–536.
- 6 **Basch, E. – Prestrud, A. A. – Hesketh, P. J., et al.:** Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*, 2011, 29, s. 4189–4198.
- 7 **Gralla, R. J. – Roila, F. – Tonato, M. – Herrstedt, J.:** MASCC/ESMO Antiemetic Guideline 2013. Dostupné z: http://www.mascc.org/assets/documents/mascc_guidelines_english_2013.pdf, vyhledáno 23. 3. 2015.
- 8 **Tomáška, M.:** Aprepitant. *Remedia*, 2009, 19, s. 3–8.
- 9 **Tomáška, M.:** Antiemetická profylaxe chemoterapií indukované nevolnosti a zvracení. *Remedia*, 2011, 21 s. 12–17.
- 10 **Tomáška, M.:** Úloha aprepitantu v antiemetické profylaxi z perspektivy doporučených postupů a úhradového omezení. *Antiemetics News*, 2014, 4 s. 11–14.
- 11 **Aapro, M. S. – Schmolli, H. J. – Jahn, F. – Carides, A. D. – Webb, R. T.:** Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. *Cancer Treatment Reviews*, 2013, 39 s. 113–117.
- 12 **Warr, D. G. – Street, J. C. – Carides, A. D.:** Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase III trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. *Support Care Cancer*, 2011, 19 s. 807–813.

Kombinovaný preparát Targin v léčbě bolesti u mnohočetného myelomu

doc. MUDr. Luděk Pour, Ph.D.

Interní hematologická a onkologická klinika LF MU a FN Brno-Bohunice

- 1 **Adam, Z. – Hájek, R. – Mayer, J., et al.:** *Multiple myeloma and other monoclonal gammopathies*. MU, Brno, 1999.
- 2 **Hájek, R.:** Základní algoritmus léčby mnohočetného myelomu. *Transfúze a hematologie dnes*, 2005, 11, dopl. 2, s. 26–30.
- 3 **Trescot, A. M. – Helm, S. – Hansen, H., et al.:** Opioids in the management of chronic cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. *Pain Physician*, 2008, 11, dopl. 2, s. 55–562.
- 4 **Ahmedzai, S. H. – Nauck, F. – Bar-Sela, G., et al.:** A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. *Palliat Med*, 2012, 26, s. 50–60.
- 5 **Schutter, U. – Grubery, S. – Meyer, C. – Schmidt, T. – Nolte, T.:** Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. *Curr Med Res Opin*, 2010, 26, s. 1377–1387.
- 6 **SPC Targin.**

Regorafenib v léčbě pokročilého gastrointestinálního stromálního tumoru

MUDr. Zdeněk Linke Onkologická klinika 2. LF UK a FN Motol, Praha
MUDr. Pavel Fencel, CSc. Oddělení nukleární medicíny a PET centrum,
Nemocnice Na Homolce, Praha

- 1 Blanke, C. – Demetri, G., et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *NEJM*, 347, 202, s. 472–480.
- 2 Rankin, C. – Von Mehren, M. – Blanke, C., et al.: Dose effect of imatinib in patients with metastatic GIST: Phase III sarcoma group study S0033 (abstrakt 9005). *Proc ASCO*, 2004, 23, s. 815.
- 3 Blay, J. Y. – Le Cesne, A., et al.: Prospective multicenter randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption vs. continuation of treatment beyond 1 year: The French Sarcoma Group. *J Clin Oncol*, 2010, 25, s. 1107–1113.
- 4 Scandinavian Sarcoma Group: Study comparing 12 months vs. 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST). SSGXVIII/AIO. Dostupné z: <http://www.clinicaltrials.gov/ct/show/NCT00116935?order=1>, vyhledáno 25. 10. 2007.
- 5 Schmieder, R. – Hoffmann, J. – Becker, M., et al.: Regorafenib (BAY 73-4506) antitumor and antimetastatic activities in preclinical models of colorectal cancer. *Int J Cancer*, 2014, 135, s. 1487–1496.
- 6 Carr, B. I. – Cavallini, A. – Lippolis, C., et al.: Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells growth inhibition, quiescence, and recovery. *J Cell Physiol*, 2013, 228, s. 292–297.
- 7 Gross, K. – Frost, A. – Steinbild, S., et al.: A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. *Clin Cancer Res*, 2012, 18, s. 2658–2667.
- 8 Grothey, A. – Van Cutsem, E. – Sombrero, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal Cancer (CORRECT); an international, multicentre, randomized, placebo-controlled, phase 3 trial. *Lancet*, 2013, 338, s. 303–312.
- 9 Li, J. – Qin, S. – Yau, T., et al.: CONCUR: a randomised, double-blind, placebo-controlled phase 3 study of regorafenib monotherapy in Asian patients with previously treated metastatic colorectal cancer (mCRC). *Ann Oncol*, 2014, 225, s. ii114–i5.
- 10 Bruix, J. – Tak, W. Y. – Gasbarrini, A., et al.: Regorafenib as second line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. *Eur J Cancer*, 2013, 49, s. 3412–3419.
- 11 Georgie, S. – Wang, Q. – Heinrich, M. C., et al.: Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. *J Clin Oncol*, 2012, 30, s. 2401–2407.
- 12 Georgie, S. – Feng, Y. – von Mehren, M., et al.: Prolonged survival and disease control in the academic phase II trial of regorafenib in GIST: response on genotype. *ASCO Meet*, 2013, 31, s. 549–558.
- 13 Demetri, G. D. – Reichardt, P. – Kang, Y. K., et al.: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*, 2013, 381, s. 295–302.

Využití bevacizumabu u nemocných s metastatickým karcinomem prsu

doc. MUDr. Luboš Holubec, Ph.D., MBA Radioterapeutická a onkologická klinika, FN a LF v Plzni,
UK v Praze, Plzeň, Biomedicínské centrum, LF v Plzni, UK v Praze, Plzeň
MUDr. Taťána Fischerová | prof. MUDr. Jindřich Fínek, Ph.D., MHA
Radioterapeutická a onkologická klinika, FN a LF v Plzni, UK v Praze, Plzeň

- 1 Rodgers, M. – Soares, M. – Epstein, D., et al.: Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer. *Health Technol Assess*, 2011, 15, dopl. 1, s. 1–12.
- 2 Pivot, X. – Schneeweiss, A. – Verma, S., et al.: Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. *Eur J Cancer*, 2011, 47, s. 2387–2395.
- 3 Kristensen, T. B. – Knutsson, M. L. – Wehland, M., et al.: Anti-vascular endothelial growth factor therapy in breast cancer. *Int J Mol Sci*, 2014, 15, s. 23024–23041.
- 4 Coussy, F. – Teixeira, L. – Giacchetti, S., et al.: New targeted therapies in breast cancer. *Gynecol Obstet Fertil*, 2014, 42, s. 787–794.
- 5 Brufsky, A.: Length of chemotherapy and use of bevacizumab for breast cancer. *Lancet Oncol*, 2014, 15, s. 1285–1287.
- 6 Keating, G. M.: Bevacizumab: a review of its use in advanced cancer. *Drugs*, 2014, 74, s. 1891–1925.
- 7 Errico, A.: Breast cancer: combining bevacizumab with chemotherapy—from maintenance to second-line treatment. *Nat Rev Clin Oncol*, 2014, 11, s. 621.
- 8 Shinoda, C. – Mori, R. – Nagao, Y.: Two cases of mastectomy after Paclitaxel + bevacizumab therapy for locally advanced breast cancer. *Case Rep Oncol*, 2014, 17, 7, s. 323–329.
- 9 Kümler, I. – Christiansen, O. G. – Nielsen, D. L.: A systematic review of bevacizumab efficacy in breast cancer. *Cancer Treat Rev*, 2014, 40, s. 960–973.
- 10 Fakhrehjani, E. – Toi, M.: Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. *Jpn J Clin Oncol*, 2014, 44, s. 197–207.
- 11 Karki, R. – Seagle, B. L. – Nieves-Neira, W. – Shahabi, S.: Taxanes in combination with biologic agents for ovarian and breast cancers. *Anticancer Drugs*, 2014, 25, s. 536–554.
- 12 Wilson, S. – Chia, S.: New agents in locally advanced breast cancer. *Curr Opin Support Palliat Care*, 2014, 8, s. 64–69.
- 13 Sochor, M. – Chlebus, P.: Antiangiogenic biotherapy and chemotherapy in breast cancer: review of literature and case report. *Clin Onkol*, 2013, 26, s. 91–98.
- 14 Kruse, V. – Denis, H. – Van Den Broecke, R., et al.: The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most? *Springerplus*, 2013, 2, s. 202.
- 15 Akker, J. L. – Meijers-Heijboer, H. – Verheul, H.: Novel strategies towards the use of anti-angiogenic agents in breast cancer. *Eur J Pharmacol*, 2013, 717, s. 36–39.
- 16 Miles, D. W.: Bevacizumab in breast cancer: fundamental questions remain. *Lancet Oncol*, 2013, 14, s. 99–101.
- 17 Rossari, J. R. – Metzger-Filho, O. – Paesmans, M., et al.: Bevacizumab and breast cancer: A meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. *J Oncol*, 2012, 8 pages.

Dolforin – klinická zkušenost v léčbě chronické bolesti u onkologických a neonkologických pacientů

MUDr. Jitka Fricová, Ph.D. KARIM, Centrum pro léčbu bolesti 1. LF UK a VFN Praha

- 1 Zecca, E. – Manzoni, A. – Centurioni, F. – Farina, A., et al.: Pharmacokinetic study between a bilayer matrix fentanyl patch and monolayer matrix fentanyl patch: single dose administration in healthy volunteers. *Format Br J Clin Pharmacol*, 22. 1. 2015, doi: 10.1111/bcp.12595.
- 2 Kang, J. H. – Oh, S. Y. – Song, S. Y., et al.: The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. *Korean J Intern Med*, 2015, 30, s. 88–95, doi: 10.3904/kjim.2015.30.188.
- 3 Mordarski, S.: Pain management in the elderly: transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee and hip. Viz komentář in: *PubMed Commons below Biomed Res Int*, 2014, 262961, doi: 10.1155/2014/262961, Epub 5. 1. 2014.
- 4 Sehgal, N. – Colson, J. – Smith, H. S.: Chronic pain treatment with opioid analgesics: benefits versus harms of long-term therapy – expert reviews. *Expert Rev Neurother*, 2013, 13, s. 1201–1220.

Aflibercept, první zkušenosti v léčbě metastatického karcinomu kolorekta

MUDr. Dagmar Brancíková | MUDr. Otakar Bednařík, CSc.
Interní hematologická a onkologická klinika, LF a FN Brno

- 1 **Allegro, C. J. – Lakomy, R. – Tabernero, J., et al.**: Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. *Journal of Clinical Oncology*, 2012, abstrakt 3505.
- 2 **Van Cutsem, E. – Tabernero, J. – Lakomy, R., et al.**: *J Clin Oncol*, 17. 9. 2012.
- 3 **Fischer, C., et al.**: *Nat Rev Cancer*, 2008, 8, s. 942–956.
- 4 **Holash, J. – Davis, S. – Papadopoulos, N., et al.**: VEGF-Trap: A VEGF blocker with potent antitumor effects. *Proc Natl Acad Sci USA*, 2001, 9, s. 11393–11398.
- 5 **Verslype, C. – Spano, C. – Van Cutsem, E., et al.**: Validation of the selected dose of aflibercept (VEGFTrap) plus irinotecan, 5-fluorouracil, and leucovorin (LV5FU2) in a phase I clinical trial of patients (pts) with advanced solid tumors (STs): Preliminary results. *J Clin Oncol*, 2008, 26, s. 631.
- 6 **Prenen, H. – Vecchione, L. – van Cutsem E.**: Role of targeted agents in metastatic colorectal cancer. *Targeted Oncology*, 2013, 8, s. 83–96.
- 7 **Bennouna, J. – Sastre, J. – Arnold, D., et al.**: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *The Lancet Oncology*, 2013, 14, s. 29–37.
- 8 **Papadopoulos, N. – Martin, J. – Ruan, J., et al.**: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. *Angiogenesis*, 2012, 15, s. 171–185.
- 9 **Grothey, A. – Van Cutsem, E. – Sombrero, A., et al.**: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*, 2013, 381, s. 303–312.

Léčba chronické myeloidní leukemie dasatinibem s pozitivním vlivem na kompenzaci diabetu

MUDr. Petra Bělohávková IV. interní hematologická klinika, FN a LF UK Hradec Králové

- 1 **Jabbour, E. – Kantarjian, H.**: Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. *Am J Hematol*, 2014, 89, s. 547–556.
- 2 **Ono, K. – Suzushima, H. – Watanabe, Y., et al.**: Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. *Intern Med*, 2012, 51, s. 2763–2766.
- 3 **Agostino, N. M. – Chinchilli, V. M. – Lunch, C. J., et al.**: Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. *J Oncol Pharm Pract*, 2011, 17, s. 197–202.

Mobilizace hematopoetických kmenových buněk plerixaforem

doc. MUDr. Jan Novák, Ph.D. Interní hematologická klinika 3. LF UK a FNKV Praha

- 1 **Kořístek, Z.**: Plerixafor. *Farmakoterapie*, 2011, 7, s. 297–306. Dostupné z: <http://www.farmakoterapie.cz/c2724/plerixafor>, vyhledáno 15. 3. 2015.
- 2 **Schols, D. – Esté, J. A. – Henson, G. – De Clercq, E.**: Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. *Antiviral Res*, 1997, 35, s. 147–156. Dostupné z: <http://www.ncbi.nlm.nih.gov/pubmed/9298754>, vyhledáno 15. 3. 2015.
- 3 **Kořístek, Z. – Pohlreich, D. – Lysák, D. – Lánská, M. – Novák, J. – Kepák, T. – Skoumalová, I. – Mužík, J.**: Mobilizace krvetvorných buněk pomocí plerixaforu – zkušenosti transplantáčních center v České republice. *Transfúze a hematologie dnes – prolékaře.cz*, 2012, 18, s. 6–12. Dostupné z: <http://www.prolekare.cz/transfuzne-hematologie-dnes-clanek/mobilizace-krvetvornych-bunek-pomoci-plerixaforu-zkusenosti-transplantačních-center-v-ceske-republice-37882>, vyhledáno 15. 3. 2015.
- 4 **Kořístek, Z.**: Současná doporučená indikační kritéria pro podání plerixaforu. *Farmakoterapie*, 2013, 9, s. 511–7. Dostupné z: <http://www.farmakoterapie.cz/c3849/soucasna-doporucena-indikacni-kriteria-pro-podani-plerixaforu>, vyhledáno 15. 3. 2015.
- 5 **To, L. B. – Levesque, J.-P. – Herbert, K. E.**: How I treat patients who mobilize hematopoietic stem cells poorly. *Blood*, 2011, 118, s. 4530–4540. Dostupné z: <http://www.ncbi.nlm.nih.gov/pubmed/21832280>, vyhledáno 15. 3. 2015.

Léčba staršího nemocného s relabující chronickou lymfocytární leukemií

MUDr. Pavel Vodárek | doc. MUDr. Lukáš Smolej, Ph.D.
IV. interní hematologická klinika, FN a LF UK Hradec Králové

- 1 **Salvi, F. – Miller, M. D. – Grilli A., et al.**: A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. *J Am Geriatr Soc*, 2008, 56, s. 1926–1931.
- 2 **Smolej et al.**: Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group. *Blood*, 2014, 124, s. 4670; publikováno před tiskem 5. 12. 2014.
- 3 **Smolej et al.**: Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite by Czech CLL Study Group. DCLLSG Combined International Workshop on CLL, Bonn, 6–7. březen 2015.

Noxafil 100 mg enterosolventní tablety (posaconazolium) – lékový profil

MUDr. Jiří Slíva, MD., Ph.D. Ústavy farmakologie 2. a 3. LF UK Praha

- 1 Keating, G. M.: Posaconazole. *Drugs*, 2005, 65, s. 1553–1567.
- 2 Krishna, G. – Ma, L. – Martinho, M. – Preston, R. A. – O'Mara, E.: A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. *J Antimicrob Chemother*, 2012, 67, s. 2725–2730.
- 3 Jung, D. S. – Tverdek, F. P. – Kontoyiannis, D. P.: Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. *Antimicrob Agents Chemother*, 2014, 58, s. 6993–6995.
- 4 McKeage, K.: Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections. *Drugs*, 2015, 75, s. 397–406.
- 5 Herbrecht, R.: Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. *Int J Clin Pract*, 2004, 58, s. 612–624.
- 6 Ezzet, F. – Wexler, D. – Courtney, R. – Krishna, G. – Lim, J. – Laughlin, M.: Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. *Clin Pharmacokinet*, 2005, 44, s. 211–220.
- 7 Courtney, R. – Pai, S. – Laughlin, M. – Lim, J. – Batra, V.: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. *Antimicrob Agents Chemother*, 2003, 47, s. 2788–2795.
- 8 Krishna, G. – Ma, L. – Martinho, M. – O'Mara, E.: Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. *Antimicrob Agents Chemother*, 2012, 56, s. 4196–4201.
- 9 Negroni, R. – Helou, S. H. – Petri, N. – Robles, A. M. – Arechavala, A. – Bianchi, M. H.: Case study: posaconazole treatment of disseminated phaeohyphomycosis due to *Exophiala spinifera*. *Clin Infect Dis*, 2004, 38, s. e15–e20.
- 10 Negroni, R. – Tobon, A. – Bustamante, B. – Shikanai-Yasuda, M. A. – Patino, H. – Restrepo, A.: Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. *Rev Inst Med Trop Sao Paulo*, 2005, 47, s. 339–346.
- 11 Tobon, A. M. – Arango, M. – Fernandez, D. – Restrepo, A.: Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. *Clin Infect Dis*, 2003, 36, s. 1488–1491.
- 12 Tobon, A. M. – Correa, A. L. – Arango, M. – de Bedout, C. – Restrepo, A.: Posaconazole therapy for severe abdominal candidiasis: a case report. *Rev Iberoam Micol*, 2004, 21, s. 79–81.
- 13 Conant, M. M. – Sha, B. E. – Proia, L. A.: Use of posaconazole delayed-release tablets for treatment of invasive aspergillosis. *Mycoses*, 2015.
- 14 Kim, M. M. – Vikram, H. R. – Kusne, S. – Seville, M. T. – Blair, J. E.: Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. *Clin Infect Dis*, 2011, 53, s. 1060–1066.
- 15 Schein, R. – Homans, J. – Larsen, R. A. – Neely, M.: Posaconazole for chronic refractory coccidioid meningitis. *Clin Infect Dis*, 2011, 53, s. 1252–1254.
- 16 Ullmann, A. J. – Lipton, J. H. – Vesole, D. H., et al.: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. *N Engl J Med*, 2007, 356, s. 335–347.
- 17 Cornely, O. A. – Maertens, J. – Winston, D. J., et al.: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med*, 2007, 356, s. 348–359.
- 18 Duarte, R. F. – Lopez-Jimenez, J. – Cornely, O. A., et al.: Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. *Antimicrob Agents Chemother*, 2014, 58, s. 5758–5765.
- 19 Wexler, D. – Courtney, R. – Richards, W. – Banfield, C. – Lim, J. – Laughlin, M.: Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. *Eur J Pharm Sci*, 2004, 21, s. 645–653.
- 20 Kraft, W. K. – Chang, P. S. – van Iersel, M. L. – Waskin, H. – Krishna, G. – Kersemaekers, W. M.: Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. *Antimicrob Agents Chemother*, 2014, 58, s. 4020–4025.